Previous studies have shown that neutrophil‐to‐lymphocyte ratio (NLR) and platelet‐to‐lymphocyte ratio (PLR) were associated with the efficacy and survival of tumor patients following anti‐PD‐1 therapy [14, 15]. This evidence concerns the gene PDCD1 and neoplasm.